drugset / Trial / NCT00038506
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.
Timeline
- Start
- 2002-03
- Primary completion
- 2004-08
- Completion
- 2004-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 300 mg | — |
| Subject | Lamivudine | Other / unclassified | 150 mg | — |
| Subject | Tenofovir | Small molecule | 300 mg | — |
| Subject | Zidovudine | Small molecule | 300 mg | — |